Hims & Hers Health Sees Unusually High Options Volume (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) saw unusually large options trading on Tuesday. Investors purchased 28,871 call options on the stock. This is an increase of approximately 249% compared to the average volume of 8,272 call options.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $12.16 on Thursday. Hims & Hers Health has a fifty-two week low of $5.65 and a fifty-two week high of $17.16. The firm has a market capitalization of $2.61 billion, a price-to-earnings ratio of -107.91 and a beta of 0.97. The stock has a 50 day moving average of $14.01 and a 200 day moving average of $10.39.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.03. The company had revenue of $278.20 million during the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. Hims & Hers Health’s revenue was up 45.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.05) earnings per share. Analysts forecast that Hims & Hers Health will post 0.11 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on HIMS shares. Leerink Partnrs restated a “market perform” rating on shares of Hims & Hers Health in a research note on Monday, February 26th. Jefferies Financial Group restated a “hold” rating and set a $15.00 price target (down previously from $17.00) on shares of Hims & Hers Health in a research note on Tuesday, April 16th. TheStreet upgraded shares of Hims & Hers Health from a “d” rating to a “c” rating in a research note on Monday, March 4th. Canaccord Genuity Group assumed coverage on shares of Hims & Hers Health in a research report on Wednesday, April 10th. They set a “buy” rating and a $20.00 target price on the stock. Finally, Truist Financial raised their price target on shares of Hims & Hers Health from $10.00 to $13.00 and gave the stock a “hold” rating in a report on Tuesday, February 27th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.07.

Insider Buying and Selling

In other news, CEO Andrew Dudum sold 97,208 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $9.58, for a total transaction of $931,252.64. Following the transaction, the chief executive officer now owns 51,653 shares in the company, valued at $494,835.74. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Hims & Hers Health news, insider Soleil Boughton sold 4,080 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $10.03, for a total transaction of $40,922.40. Following the completion of the sale, the insider now owns 154,345 shares in the company, valued at $1,548,080.35. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Andrew Dudum sold 97,208 shares of the stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $9.58, for a total value of $931,252.64. Following the sale, the chief executive officer now directly owns 51,653 shares in the company, valued at approximately $494,835.74. The disclosure for this sale can be found here. Insiders have sold a total of 736,191 shares of company stock valued at $9,733,700 over the last quarter. 31.63% of the stock is owned by corporate insiders.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new stake in Hims & Hers Health during the 3rd quarter worth about $280,000. Bank of New York Mellon Corp increased its stake in shares of Hims & Hers Health by 11.5% during the third quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company’s stock worth $3,551,000 after buying an additional 58,288 shares during the period. Mackenzie Financial Corp raised its holdings in Hims & Hers Health by 354.2% in the third quarter. Mackenzie Financial Corp now owns 51,243 shares of the company’s stock valued at $318,000 after acquiring an additional 39,962 shares in the last quarter. Strs Ohio lifted its stake in Hims & Hers Health by 33.0% in the third quarter. Strs Ohio now owns 102,000 shares of the company’s stock worth $641,000 after acquiring an additional 25,300 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its holdings in Hims & Hers Health by 7.4% during the 3rd quarter. Teacher Retirement System of Texas now owns 72,253 shares of the company’s stock worth $454,000 after acquiring an additional 4,954 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.